MARKET

IMUC

IMUC

Immunocellular
OTCPK
0.700
+0.190
+37.25%
Closed 15:41 09/28 EDT
OPEN
0.450
PREV CLOSE
0.510
HIGH
0.700
LOW
0.450
VOLUME
5.82K
TURNOVER
3.87K
52 WEEK HIGH
0.800
52 WEEK LOW
0.140
MARKET CAP
79.29M
P/E (TTM)
-16.0920
1D
5D
1M
3M
1Y
5Y
EOM Pharmaceuticals files to uplist to Nasdaq
EOM Pharmaceuticals (OTCPK:IMUC) has filed to uplist from the Pink Sheets to the Nasdaq. As part of the application, EOM would trade on the Nasdaq under the ticker "EOM." EOM
Seekingalpha · 06/24 21:06
ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will be applicable in September 2021. The amended Rule requir...
PR Newswire · 06/28/2021 10:00
ImmunoCellular Therapeutics Announces Results of Special Meeting of Stockholders Held June 26, 2020
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that, based on the vote count following the Special Meeting of Stockholders held June 26, 2020, stockholders voted in favor of the proposal to approve an amendment to the Company
PR Newswire · 07/02/2020 20:05
ImmunoCellular Therapeutics Announces Settlement of Derivative Action Lawsuit
PR Newswire · 10/16/2019 20:05
About IMUC
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

Webull offers kinds of ImmunoCellular Therapeutics Ltd stock information, including OTCPK:IMUC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMUC stock methods without spending real money on the virtual paper trading platform.